title: Analysis of Prethrombotic States in Patients with Malignant Tumors.
abstract: BACKGROUND
  This study aimed to investigate the incidence and risk factors for a prethrombotic state in patients with malignant tumors.
  
  
  METHODS
  Plasma d-dimer (D-D) in patients with malignant tumors was measured. Abnormal rates of D-D and possible risk factors like gender, age, type of tumor, and staging of tumor were analyzed.
  
  
  RESULTS
  Of 1,453 patients, 629 demonstrated plasma D-D abnormality (43.3%). The D-D abnormal rate of male patients (n=851, 43.5%) was not statistically significantly different from that for female patients (n=602, 43.0%) (p>0.05). D-D abnormal rate increased with age and was statistically significant among different age groups (p<0.05). Regarding staging of tumor, D-D abnormal rate in patients with phase I was 2.0%, 6.2% in phase II, 47.6% in phase III and 83.1% in phase IV, with statistically significant differences between phase III and II, as well as phase III and IV (p<0.01).
  
  
  CONCLUSIONS
  A prethrombotic state was closely related to malignancy of tumors. The risk factors for a prethrombotic state include age and tumor stage.
authors.affiliation: Department of Oncology, Taizhou Second People's Hospital, the Affiliated Hospital of Yangzhou University, Taizhou, China E-mail : huangxinen06@163.com.
authors.forename: Lin
authors.initials: L
authors.lastname: Cui
authors.forename: You-Hong
authors.initials: YH
authors.lastname: Sun
authors.forename: Jue
authors.initials: J
authors.lastname: Chen
authors.forename: Lu
authors.initials: L
authors.lastname: Wang
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Liu
authors.forename: Xiang-Rong
authors.initials: XR
authors.lastname: Zhou
authors.forename: Jie
authors.initials: J
authors.lastname: Ding
authors.forename: Xing-Xiang
authors.initials: XX
authors.lastname: Liu
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000933:Antifibrinolytic Agents / Q000032:analysis; D015415:Biomarkers / Q000097:blood*; D001798:Blood Proteins / Q000032:analysis; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000150:complications* / Q000473:pathology; D011379:Prognosis; D013927:Thrombosis / Q000097:blood / Q000175:diagnosis* / Q000209:etiology
chemical_list: D000933:Antifibrinolytic Agents; D015415:Biomarkers; D001798:Blood Proteins; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D